Biomarker signatures identified through minimally invasive procedures already at diagnosis of
non-small-cell lung cancer (NSCLC) could help to guide treatment with
immune checkpoint inhibitors (ICI). Here, we performed multiplex profiling of immune-related
proteins in fine-needle aspirate (FNA) samples of thoracic lesions from patients with NSCLC to assess PD-L1 expression and identify related
protein signatures. Transthoracic FNA samples from 14 patients were subjected to multiplex antibody-based profiling by proximity extension assay (PEA). PEA profiling employed
protein panels relevant to immune and
tumor signaling and was followed by Qlucore® Omics Explorer analysis. All lesions analyzed were NSCLC
adenocarcinomas, and PEA profiles could be used to monitor 163
proteins in all but one sample. Multiple key immune signaling components (including CD73,
granzyme A, and
chemokines CCL3 and CCL23) were identified and expression of several of these
proteins (e.g., CCL3 and CCL23) correlated to PD-L1 expression. We also found EphA2, a marker previously linked to inferior NSCLC prognosis, to correlate to PD-L1 expression. Our identified
protein signatures related to stage included, among others, CXCL10 and IL12RB1. We conclude that transthoracic FNA allows for extensive immune and
tumor protein profiling with assessment of putative
biomarkers of important for ICI treatment selection in NSCLC.